Raynaud's phenomenon

Rheumatic Disease Clinics of North America

Volumn 22, Issue 4, 1996, Pages 765-781

  Wigley, F M ^a   Flavahan, N A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PROSTAGLANDIN;

CONNECTIVE TISSUE DISEASE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SYMPTOM;

EID: 0029855694     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70300-8     Document Type: Article

References (121)

1. E.L. Alexander G.S. Firestein J.L. Weiss Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis Ann Intern Med 105 1986 661 668
2. E.V. Allen G.E. Brown Raynaud's disease: A critical review of minimal requisites for diagnosis Am J Med Sci 183 1932 187 200
3. R.J. Barst L.J. Rubin W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 301
4. M.L. Bartelink H. Wollersheim E. Leesmans A standardized finger cooling test for Raynaud's phenomenon: Diagnostic value and sex differences Eur Heart J 14 1993 614 622
5. M.L. Bartelink H. Wollersheim E. van de Lisdonk Prevalence of Raynaud's phenomenon Neth J Med 41 1992 149 152
6. G.V. Bedarida D. Kim T.F. Blaschke Venodilation in Raynaud's disease Lancet 342 1993 1451 1454
7. J.J. Belch H.A. Capell E.D. Cooke Oral iloprost as a treatment for Raynaud's syndrome: A double-blind multicentre placebo-controlled study Ann Rheum Dis 54 1995 197 200
8. J.J.F. Belch J.K. Drury H. Capell Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome Lancet 1 8320 1983 313 315
9. A.D. Blann K. Illingworth M.I.V. Jayson Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon J Rheumatol 20 1993 1325 1330
10. W. Bottomley M. Goodfield A pathogenic role for endothelin in Raynaud's phenomenon? Acta Derm Venereol 74 1994 433 434
11. P. Brennan A. Silman C. Black Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group Br J Rheumatol 32 1993 357 361
12. R.M. Brouwer G.J. Wenting M.A. Schalekamp Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon J Cardiovasc Pharmacol 15 1990 868 876
13. C.B. Bunker G. Terenghi D.R. Springall Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon Lancet 336 1990 1530 1533
14. D.B. Bylund J.W. Regan J.E. Faber Vascular α-adrenoceptors: From the gene to the human Can J Physiol Pharmacol 73 1995 533 543
15. P.M. Campbell E.C. LeRoy Pathogenesis of systemic sclerosis: A vascular hypothesis Semin Arthritis Rheum 4 1975 351 368
16. P.J. Cannon M. Hassar D.B. Case The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and function abnormalities of the renal cortical circulation Medicine 53 1974 1 46
17. P.H. Carpentier H.R. Maricq Microvasculature in systemic sclerosis Rheum Dis Clin North Am 16 1990 75 91
18. V.F. Challenor Angiotensin converting enzyme inhibitors in Raynaud's phenomenon Drugs 48 1994 864 867
19. J.D. Coffman D.L. Clement M.A. Creager International study of ketanserin in Raynaud's phenomenon Am J Med 87 1989 264 268
20. J.D. Coffman A.S. Cohen Total and capillary fingertip blood flow in Raynaud's phenomenon N Engl J Med 29 1971 259 263
21. 2 receptor hypersensitivity in Raynaud's disease J Vasc Med Biol 2 1990 100 106
22. J.D. Coffman R.A. Cohen Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits Eur J Clin Invest 18 1988 309 313
23. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud's phenomenon French Cooperative Multicenter Group for Raynaud's Phenomenon, Paris, France Am Heart J 122 1991 352 355
24. L. Dabich J.J. Bookstein A. Zweifler Digital arteries in patients with scleroderma Arch Intern Med 130 1972 708 714
25. J.M. Destors E. Gauthier S. Lelong Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon Angiology 37 1986 565 569
26. M.I. Dorevitch L.E. Clemens J.B. Webb Lower limb amputation secondary to large vessel involvement in scleroderma Br J Rheumatol 27 1988 403 406
27. L. Ekenvall L.E. Lindblad O. Norbreck α-Adrenoceptors and cold-induced vasoconstriction in human finger skin Am J Physiol 255 1988 H1000 H1003
28. W.H. Ettinger R.A. Wise D. Schaffhauser Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon Am J Med 77 1984 456 461
29. A.E. Flatt Digital arterial sympathectomy J Hand Surg [Am] 8 1983 283 288
30. 2-adrenoceptors: Differential distribution in limb arteries J Pharmacol Exp Ther 241 1987 361 365
31. 2-adrenergic responses in cutaneous veins: Role of receptor-reserve Am J Physiol 249 1985 H950 H955
32. 1-adrenergic responses in canine saphenous veins J Pharmacol Exp Ther 240 1987 589 593
33. N.A. Flavahan P.M. Vanhoutte Endothelial cell signalling and endothelial dysfunction Am J Hypertens 8 suppl 1995 28 41
34. 2-adrenergic responses in canine saphenous and femoral veins J Pharmacol Exp Ther 238 1986 139 147
35. 1-Adrenoceptor. 1987 Humana Press New York 351 403
36. N.A. Flavahan P.M. Vanhoutte Sympathetic purinergic vasoconstriction and thermosensitivity in a canine cutaneous vein J Pharmacol Exp Ther 239 1986 784 788
37. R. Fleischmajer J.S. Perlish Thymidine labeling of dermal endothelial cells in scleroderma J Invest Dermatol 69 1977 379 382
38. N. Francaviglia C. Sivestro M. Maiello Spinal cord stimulation for the treatment of progressive systemic sclerosis and Raynaud's syndrome Br J Neurosurg 8 1994 567 571
39. C. Franssen H. Wollersheim A. de Haan The influence of different beta-blocking drugs on the peripheral circulation in Raynaud's phenomenon and in hypertension J Clin Pharmacol 32 1992 652 659
40. R.R. Freedmann Quantitative measurements of finger blood flow during behavioral treatments for Raynaud's disease Psychophysiology 26 1989 437 441
41. 1-adrenergic antagonists in idiopathic Raynaud's disease Circulation 92 1995 1448 1451
42. R.R. Freedman P. Ianni Wenig Behavioral treatment of Raynaud's phenomenon in scleroderma J Behav Med 7 1984 343 353
43. 2-adrenergic vasoconstriction in primary Raynaud's disease Arthritis Rheum 36 1993 685 690
44. A.J. Freemont J. Hoyland P. Fielding Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: Direct evidence for a generalized microangiopathy Br J Dermatol 126 1992 561 568
45. R.F. Furchgott P.M. Vanhoutte Endothelium-derived relaxing and contracting factors FASEB J 3 1989 2007 2018
46. U.C. Garg A. Hassid Nitric oxide generating vasodilators and 8-bromo-cycle GMP inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells J Clin Invest 83 1990 1774 1777
47. P. Gasser Muller D. Mauli Evaluation of reflex cold provocation by laser Doppler flowmetry in clinically healthy subjects with a history of cold hands. Angiology 43:389–394, 1992 47a. Gastaud M, Dolisi C, Bermon S, et al: Short term effect of cold provocation on single-breath carbon monoxide diffusing capacity in subjects with and without Raynaud's phenomenon Clin Exp Rheumatol 13 1995 617 621
48. M.J.D. Goodfield A. Hume N.R. Rowe The acute effects of smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon Br J Rheumatol 29 1990 89 91
49. M.J. Goodfield A. Hume N.R. Rowell The effect of simple warming procedures of finger blood flow in systemic sclerosis Br J Dermatol 118 1988 661 668
50. M.S. Gruschwitz O.P. Hornstein P. Vondendriesch Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity Arthritis Rheum 38 1995 184 189
51. O. Henriksen K. Kristensen Reduced systolic blood pressure in fingers of patients with generalized scleroderma (acrosclerosis) Acta Derm Venereol 61 1981 531 534
52. A.L. Herrick M. Heaney S. Hollis Anticardiolipin, anticentromere, and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia Ann Rheum Dis 53 1994 540 542
53. A.L. Herrick K. Illingworth A. Blann Von Willebrand factor, thrombomodulin thromboxane, β-thromboglobulin, and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis Ann Rheum Dis 55 1996 122 127
54. 1-adrenoceptors: Consensus update Pharmacol Rev 47 1995 267 270
55. J. Hutchison Raynaud's phenomenon Med Press 123 1901 403 405
56. W.J. Janssens T.J. Verbeuren P.M. Vanhoutte Effect of moderate cooling on adrenergic neuroeffector interaction in canine cutaneous veins Blood Vessels 18 1981 281 295
57. M.B. Kahaleh Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action Arthritis Rheum 34 1991 978 983
58. C.G.M. Kallenberg Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions Curr Opinion Rheumatol 7 1995 568 573
59. C.G.M. Kallenberg A.A. Wouda M.H. Hoet Development of connective tissue disease in patients presenting with Raynaud's phenomenon: A 6-year follow-up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting Ann Rheum Dis 47 1988 634 641
60. S. Kazandjian J.-N. Fiessinger J.-P. Camilleri Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): An in vitro autoradiographic study Acta Derm Venereol 62 1982 425 461
61. F. Khan J.D. Coffman Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon Circulation 89 1994 1183 1188
62. H. Kiener W. Graninger K. Machold Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis Clin Exp Rheumatol 12 1994 483 487
63. P.S. Klimiuk E.A. Kay K.J. Illingworth A double-blind placebo controlled trial of recombinant tissue plasminogen activator in the treatment of digital ischemia in systemic sclerosis J Rheumatol 19 1992 716 720
64. G.A. Knock G. Terenghi C.B. Bunker Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis J Invest Dermatol 101 1993 73 78
65. I. Kurose D.N. Granger Evidence implicating xanthine oxidase and neutrophils in reperfusion-induced microvascular dysfunction Ann NY Acad Sci 723 1994 158 179
66. G.J. Landry J.M. Edwards R.B. McLafferty Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort J Vasc Surg 23 1996 76 85
67. 1 infusions J Rheumatol 16 1989 1433 1435
68. C.S. Lau J.J. Belch R. Madhok A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis Clin Exp Rheumatol 11 1993 35 40
69. E.C. LeRoy T.A. Medsger Jr Raynaud's phenomenon: A proposal for classification Clin Exp Rheumatol 10 1992 485 488
70. T. Lewis Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation of the fingers. A variety of Raynaud's disease Heart 14 1929 7 101
71. L.E. Lindblad L. Ekenvall B.M. Etzell Adrenoceptors in Raynaud's disease J Cardiovasc Pharmacol 14 1989 881 885
72. Q. Liu C.M. Wiener R.J. Spence Vasomotor dysfunction in isolated microvessels of patients with scleroderma Arthritis Rheum 38 suppl 1995 252
73. B. Marasini M. Cugno C. Bassani Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon Int J Microcirc Clin Exp 11 1992 375 382
74. H.R. Maricq Capillary abnormalities, Raynaud's phenomenon, and systemic sclerosis in patients with localized scleroderma Arch Dermatol 128 1992 630 632
75. H.R. Maricq P.H. Carpentier M.C. Weinrich Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, versus Tarentaise, Savoie, France J Rheumatol 20 1993 70 76
76. H.R. Maricq F. Diat M.C. Weinrich Digital pressure responses to cooling in patients with suspected early versus definite scleroderma (systemic sclerosis) versus primary Raynaud's phenomenon J Rheumatol 21 1994 1472 1476
77. H.R. Maricq M.D. Weinrich Diagnosis of Raynaud's phenomenon assisted by color charts J Rheumatol 15 1988 454 459
78. A. Marshall D.W. Barritt C.J. Roberts Letter: Raynaud's phenomenon as side effect of beta-blockers BMJ 2 1976 301
79. T. Masaki Possible role of endothelin in endothelial regulation of vascular tone Ann Rev Pharmacol Toxicol 35 1995 235 255
80. M.D. Menger Microcirculatory disturbances secondary to ischemia-reperfusion Transplant Proc 27 1995 2863 2865
81. 1 in Raynaud's phenomenon Ann Rheum Dis 44 1985 754 760
82. S. Moncada R.M.J. Palmer E.A. Higgs Nitric oxide: Physiology, pathophysiology, and pharmacology Pharmacol Rev 43 1991 109 142
83. J.L. Morris I.L. Gibbins P.J. Kadowitz Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons Can J Physiol Pharmacol 73 1995 521 532
84. C. Mruai T. Sasaki H. Osaki Oral limaprost for Raynaud's phenomenon Lancet 18 1989 1218
85. S.L. Nielsen Raynaud's phenomena and finger systolic pressure during cooling Scand J Clin Lab Invest 38 1978 765 770
86. W.L. Norton J.M. Nardo Vascular disease in progressive systemic sclerosis (scleroderma) Ann Intern Med 73 1970 317 324
87. B.M.C. O'Brien P.A.U. Kuman C.G. Mellow T.V. Oliver Radial microarteriolysis in the treatment of vasospastic disorders of the hand, especially scleroderma J Hand Surg [Br] 17 1992 447 452
88. S.T. O'Keeffe N.P. Tsapatsaris W.P. Beetham Jr Color chart–assisted diagnosis of Raynaud's phenomenon in an unselected hospital employee population J Rheumatol 19 1992 1415 1417
89. N. Olsen S.L. Nielsen Prevalence of primary Raynaud's phenomena in young females Scand J Clin Lab Invest 38 1978 761 764
90. J.D. Pearson The endothelium: Its role in scleroderma Ann Rheum Dis 50 1991 866 871
91. J.M. Porter E.J. Bardana Jr G.M. Baur The clinical significance of Raynaud's syndrome Surgery 80 1976 756 764
92. R.J. Prescott A.J. Freemont C.J. Jones Sequential dermal microvascular and perivascular changes in the development of scleroderma J Pathol 166 1992 255 263
93. M. Rademaker E.D. Cooke N.E. Almond Comparison of intravenous infusions of iloprost and oral nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis: A double-blind randomized study BMJ 298 1989 561 563
94. M. Rademaker R.H. Meyrick Thomas J.D. Kirby The anti-platelet effect of nifedipine in patients with systemic sclerosis Clin Exp Rheumatol 10 1992 57 62
95. M. Raynaud On local asphyxia and symmetrical gangrene of the extremities T. Barlow Selected Monographs, 121. 1888 The Syndenham Society London 1 199 trans
96. G. Riera M. Vilardell J. Vaque Prevalence of Raynaud's phenomenon in a healthy Spanish population J Rheumatol 20 1993 66 69
97. T. Sakurai K. Goto Endothelins: Vascular actions and clinical implications Drugs 46 1993 795 804
98. P.P. Sfikakis M. Kyriakidis C. Vergos Diffusing capacity of the lung and nifedipine in systemic sclerosis Arthritis Rheum 33 1990 1634 1639
99. S. Shawket C. Dickerson B. Hazleman Prolonged effect of CGRP in Raynaud's patients: A double-blind randomized comparison with prostacyclin Br J Clin Pharmacol 34 1991 209 213
100. J.W. Shuck W.J. Oetgen J.T. Tesar Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis Am J Med 78 1985 221 227
101. A. Silman S. Hollingan P. Brennan Prevalence of symptoms of Raynaud's phenomenon in general practice BMJ 22 1990 590 592
102. J.L. Silverstein V.D. Steen Medsger T.A. Jr Cutaneous hypoxia in patients with systemic sclerosis Arch Dermatol 124 1988 1379 1382
103. E.J. ter Borg G. Piersma-Wichers A.J. Smit Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma Semin Arthritis Rheum 24 1994 40 47
104. N. Toda Regulation of blood pressure by nitroxidergic nerve J Diabetes Complications 9 1995 200 202
105. H. Tsukamoto K. Nagasawa Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue Br J Rheumatol 30 1991 317
106. R. Vancheeswaran A. Azam C. Black Localization of endothelin-1 and its binding sites in scleroderma skin J Rheumatol 21 1994 1268 1276
107. P.M. Vanhoutte Other endothelium-derived vasoactive factors Circulation 87 1993 V9 V17
108. E.S. Weiner S. Hildebrandt J.L. Senecal Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study Arthritis Rheum 34 1991 68 77
109. M.C. Weinrich H.R. Maricq J.E. Keil Prevalence of Raynaud's phenomenon in the adult population of South Carolina J Clin Epidemiol 43 1990 1343 1349
110. A.K. Wiencke H. Nilsson P.J. Nielsen Nonadrenergic noncholinergic vasodilation in bovine ciliary artery involves CGRP and nitric oxide Invest Opthalmol Vis Sci 35 1994 3268 3277
111. F.M. Wigley J.R. Seibold R.A. Wise D.A. McCloskey W.P. Dole Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis J Rheumatol 19 1992 1407 1413
112. F.M. Wigley R.A. Wise J.R. Seibold Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis Ann Intern Med 120 1994 199 206
113. F.M. Wigley R.A. Wise M.B. Stevens The effect of cold exposure on carbon monoxide diffusing capacity in patients with Raynaud's phenomenon Chest 81 1982 695 698
114. F.M. Wigley R.A. Wise R. Malamet Nicardipine in the treatment of Raynaud's phenomenon Arthritis Rheum 30 1987 281 286
115. F.M. Wigley R.A. Wise J. Mikdashi The post-occlusive hyperemic response in patients with systemic sclerosis Arthritis Rheum 33 1990 1620 1625
116. F.M. Wigley R.A. Wise R. Miller Anticentromere antibody predicts the ischemic loss of digits in patients with systemic sclerosis Arthritis Rheum 35 1992 688 693
117. R.A. Wise F.M. Wigley Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon J Rheumatol 21 1994 80 83
118. H. Wollersheim T. Thien M.H. Hoet The diagnostic value of several immunologic tests for antinuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon Eur J Clin Invest 19 1989 535 541
119. M. Yanagisawa H. Kurihara S. Kimura A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 1988 411 415
120. P. Youssef H. Englert J. Bertouch Large vessel occlusive disease associated with CREST syndrome and scleroderma Ann Rheum Dis 52 1993 464 466
121. M.R. Zamora R.F. O'Brien R.B. Rutherford Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon Lancet 336 1990 1144 1147